INNOVA MEDICAL GROUP’S COVID-19 ECOSYSTEM IS DELIVERING MILLIONS OF TESTS EVERY DAY TO SATISFY THE DIVERSE, POINT-OF-CARE REQUIREMENTS OF THE WORLD'S GOVERNMENTS, LARGE CORPORATIONS, AND INSTITUTIONS
INNOVA MEDICAL GROUP PRESENTS
The INNOVA Rapid Antigen Test demonstration conducted by
Dr. Rachel Limbrey, MBBS, DM, FRCP
Consultant Respiratory, Physician, &
Honorary Senior Clinical Lecturer
University Hospital Southampton, England
ACCURATE + EASY-TO-USE + SCALABLE
The INNOVA SARS-CoV-2 Antigen Rapid Qualitative Test offers a combined accuracy of 98.98%, is easy to administer, and offers point-of-care results in minutes.
WATCH THE INNOVA RAPID ANTIGEN TEST PERFORMED
The INNOVA antigen test can be performed and processed on-site (POCT) and detects the virus in the same time-frame (post-infection) as PCR swab tests.
MAXIMIZING THE VALUE OF NOVEL MEDICAL DEVICES, GLOBALLY
We discover opportunities for top talents and the most promising innovative medical technologies by conducting fundamental research. Our hands-on approach benefits all parties by utilizing minimal capital for maximum returns.
GLOBAL MARKET ORIENTATION
We invest in innovative healthcare technologies and help breakthrough, medical device companies penetrate the global market with the most cost-effective, efficient strategies for reaching customers and controlling risk by mobilizing our worldwide network and partnerships.